Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma.
It also develops the enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jul 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Paul-Peter Tak |
Contact Details
Address: 117 Kendrick Street, Suite 450 Needham, Massachusetts 02494 United States | |
| Phone | 617 916 5445 |
| Website | candeltx.com |
Stock Details
| Ticker Symbol | CADL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001841387 |
| CUSIP Number | 137404109 |
| ISIN Number | US1374041093 |
| Employer ID | 52-2214851 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Charles Schoch | Interim Chief Financial Officer, Principal Accounting Officer, Treasurer and Secretary |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical and Development Officer |
| Ileen B. Winick | Chief People Officer |
| Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 13, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 424B5 | Filing |
| Dec 12, 2024 | 424B5 | Filing |
| Dec 11, 2024 | 8-K | Current Report |
| Nov 29, 2024 | 144 | Filing |
| Nov 29, 2024 | 144 | Filing |
| Nov 29, 2024 | 144 | Filing |
| Nov 29, 2024 | 144 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |